BioSpace4h
Gilead Passes on Option for Arcus’ Cancer Drug Despite Strong Early Data
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...
PharmiWeb8h
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...
Managed Healthcare Executive17h
FDA Approves NDA for Gilead's new HIV Prevention Shot
Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...
Fintel on MSN18h
Deutsche Bank Upgrades Gilead Sciences (GILD)
Fintel reports that on February 18, 2025, Deutsche Bank upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Gilead Sciences Inc. closed 1.35% below its 52-week high of $106.69, which the company achieved on February 14th.
Gilead opts out of deal for Arcus cancer therapy
Arcus Biosciences (RCUS) stock falls as Gilead (GILD) decides not to buy rights to its anticancer drug casdatifan. Read more ...
Gilead upped on HIV franchise; Merck downgraded on Keytruda LoE at Deutsche Bank
Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, ...